Description: The growth of the life insurance industry in Bermuda has been remarkable over the past several years. What may have been just a handful of commercial life insurance companies with operations on the island just a few years ago, has now mushroomed into nearly 200 registered companies.With a stable economy, robust regulatory framework, and tax-efficient environment, companies are increasingly looking to Bermuda when making strategic decisions.This session takes a case study approach in illustrating the financial implications that can lead to a strategic decision to put business into Bermuda. Other practical considerations such as investment portfolio opportunities, guideline interpretation, and tax status, are also explored By attending the session, you will: - Analyze the balance sheet complexities under the Bermuda regime. - Understand the implications of offshore reinsurance on distributable earnings and embedded value. - Develop knowledge on the impact of incorporating alternative assets on Bermuda required capital and EV. - Understand the practical considerations in reinsuring business offshore to Bermuda.

Description: LDTI requires that reinsurance recoverables be recognized in a manner consistent with the liabilities of underlying direct contracts. Consider implications of multiple ceded reinsurance contracts (e.g., coinsurance and YRT on the same business) and how this impacts the calculation of the net premium ratio (NPR) and other related approximations. Explore different options when only some of the policies within a cohort are reinsured. Multiple interpretations of the components of the NPR formula exist. Two main approaches will be presented-standalone and integrated approach. Other considerations to be discussed include implications of closed-block reinsurance transactions at transition and subsequent to transition, contra-DAC, market risk benefits. Finally, explore the short-duration YRT approximation (1/2 Cx) compared to the long-duration calculation.

Description: Review the Bermuda Monetary Authority's Consultation Paper I and focus on required changes to governance, risk management, modeling, lapse risk, filing requirements, model governance and more.

Description: Discover investing trends across the life and health industry as insurers seek to navigate rapidly changing rate and market environments. BlackRock will present results from its Peer Risk Study, which models industry holdings based on statutory filings at the CUSIP level. Through the Aladdin risk modeling software, expect a production of deep insights into insurer portfolio risk and return characteristics, as well as exploring how they have evolved. Keep an eye out for a partner to present on the evolution from their perspective. Start learning about what is happening on the asset side of the balance sheet across the industry.

Description: 2021 Life Meeting - Session 8E: Insurance M&A Valuation Methodologies and Considerations 9.1.21 Recording

Description: Join us for the It Takes a Village: Insurance Product Development in the Digital webcast. Focuses will be directed toward a variety of disciplines within the actuarial science industry. We will also take a deep dive into UW, Technology Product and Marketing and Distribution. Don't miss the opportunity to bring digital insurance products to life and discover what the process of product evolution.

Description: In this panel discussion, actuarial leaders in the stop-loss marketplace provide their perspectives on recent stop-loss trends. Learn about the most current issues facing self-funded plans and their stop-loss coverage. Take part in a deeper discussion on this topic and more at Oysters, Beers & Large Claim Solutions on Tuesday, June 27, from 4:30-5:30 p.m. PT. This happy hour, featuring drinks and tasty Pacific Northwest oysters will include a discussion on the large claims impacts on the health care market.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.

Description: ClubVita Session Series Longevity trend risk still exists even for the largest portfolios. Explore the differences in longevity improvements between different populations, how to categorize subpopulations with different trend risk characteristics, and how to use this categorization to reduce longevity trend basis risk.

Description: Learn about considerations and industry observed trends which cover different ways companies try to manage their inforce business in low and rapidly rising interest environments. You will explore M&A, block transaction, and offshore reinsurance solutions.